|
|
Post by ppallap on Apr 29, 2020 22:50:24 GMT -5
Interview with Gilead CEO today. www.msn.com/en-us/finance/markets/gilead-ceo-says-over-50000-remdesivir-courses-ready-to-ship/ar-BB13oJre The following statement is interesting: " The current version of the drug is infused, which would make it less convenient to use in milder patients who are not hospitalized. O’Day said Gilead scientists are devising an inhaled formulation of the drug that would allow patients to breathe the medicine directly into their lungs. “We are moving with speed on it,” he said. He said he couldn’t give a timeline of when patient trials of the inhaled form would begin. " |
|
|
|
Post by goyocafe on Apr 30, 2020 1:08:12 GMT -5
Interview with Gilead CEO today. www.msn.com/en-us/finance/markets/gilead-ceo-says-over-50000-remdesivir-courses-ready-to-ship/ar-BB13oJre The following statement is interesting: " The current version of the drug is infused, which would make it less convenient to use in milder patients who are not hospitalized. O’Day said Gilead scientists are devising an inhaled formulation of the drug that would allow patients to breathe the medicine directly into their lungs. “We are moving with speed on it,” he said. He said he couldn’t give a timeline of when patient trials of the inhaled form would begin. " That is interesting. Imagine if they can develop a novel inhalation technology faster than MC can call Gilead and show them they can formulate one with Technoshpere in less time. I just hope MC has his ear to the ground. These opportunities are just hanging on the bottom branches. |
|
|
|
Post by peppy on Apr 30, 2020 5:52:50 GMT -5
Interview with Gilead CEO today. www.msn.com/en-us/finance/markets/gilead-ceo-says-over-50000-remdesivir-courses-ready-to-ship/ar-BB13oJre The following statement is interesting: " The current version of the drug is infused, which would make it less convenient to use in milder patients who are not hospitalized. O’Day said Gilead scientists are devising an inhaled formulation of the drug that would allow patients to breathe the medicine directly into their lungs. “We are moving with speed on it,” he said. He said he couldn’t give a timeline of when patient trials of the inhaled form would begin. " Yes, this is our ticket. GILD could buy MNKD in a blink of an eye? Effective drug delivery system. |
|
|
|
Post by neil36 on Apr 30, 2020 8:55:14 GMT -5
A good analyst should make this their first question on the earnings call. Have their been any conversations with Gilead with regards to their stated goal of an inhaled version of Remdesivir?
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Apr 30, 2020 9:28:27 GMT -5
A good analyst should make this their first question on the earnings call. Have their been any conversations with Gilead with regards to their stated goal of an inhaled version of Remdesivir? That would be a BAD question because he does not know the answer. If Mike answered NO....it could hurt the stock price. And Mike wont say yes because they are still working out the details of a possible collaboration. |
|
|
|
Post by mango on Apr 30, 2020 9:45:48 GMT -5
Interview with Gilead CEO today. www.msn.com/en-us/finance/markets/gilead-ceo-says-over-50000-remdesivir-courses-ready-to-ship/ar-BB13oJre The following statement is interesting: " The current version of the drug is infused, which would make it less convenient to use in milder patients who are not hospitalized. O’Day said Gilead scientists are devising an inhaled formulation of the drug that would allow patients to breathe the medicine directly into their lungs. “We are moving with speed on it,” he said. He said he couldn’t give a timeline of when patient trials of the inhaled form would begin. " • MannKind specializes in DPI development and rare lung diseases. • MannKind has patented protected: inhalation devices, dry powder technology, and manufacturing methods and processes and uses, etc... Inhaled Remdesivir Technosphere would be safe from competitors for many years to come. • MannKind has the manufacturing space ready. • MannKind has multiple inhaler designs ready. • MannKind has proven success in developing DPI medicines and a 100% FDA product approval success rate. |
|
|
|
Post by JEvans on Apr 30, 2020 10:18:55 GMT -5
Interview with Gilead CEO today. www.msn.com/en-us/finance/markets/gilead-ceo-says-over-50000-remdesivir-courses-ready-to-ship/ar-BB13oJre The following statement is interesting: " The current version of the drug is infused, which would make it less convenient to use in milder patients who are not hospitalized. O’Day said Gilead scientists are devising an inhaled formulation of the drug that would allow patients to breathe the medicine directly into their lungs. “We are moving with speed on it,” he said. He said he couldn’t give a timeline of when patient trials of the inhaled form would begin. " • MannKind specializes in DPI development and rare lung diseases. • MannKind has patented protected: inhalation devices, dry powder technology, and manufacturing methods and processes and uses, etc... Inhaled Remdesivir Technosphere would be safe from competitors for many years to come. • MannKind has the manufacturing space ready. • MannKind has multiple inhaler designs ready. • MannKind has proven success in developing DPI medicines and a 100% FDA product approval success rate. You say this why? Who are you? As if you are a decision maker for Mannkind. You say Mannkind has proven success? I've been following Mannkind for 8 years. You have a strange definition for success, unless your talking about losing $, tooting their own horns, and steeling from peter to pay paul. |
|
|
|
Post by mango on Apr 30, 2020 10:27:38 GMT -5
• MannKind specializes in DPI development and rare lung diseases. • MannKind has patented protected: inhalation devices, dry powder technology, and manufacturing methods and processes and uses, etc... Inhaled Remdesivir Technosphere would be safe from competitors for many years to come. • MannKind has the manufacturing space ready. • MannKind has multiple inhaler designs ready. • MannKind has proven success in developing DPI medicines and a 100% FDA product approval success rate. You say this why? Who are you? As if you are a decision maker for Mannkind. You say Mannkind has proven success? I've been following Mannkind for 8 years. You have a strange definition for success, unless your talking about losing $, tooting their own horns, and steeling from peter to pay paul. I said MannKind has proven success in developing DPI medicines. See: Afrezza, Treprostinil Technosphere, and the Pipeline. MannKind currently has a 100% success rate with FDA product approval. Their first biological product (Afrezza) that they developed for FDA approval was approved. That equates to a 100% FDA product approval success rate. |
|
|
|
Post by JEvans on Apr 30, 2020 10:39:58 GMT -5
You say this why? Who are you? As if you are a decision maker for Mannkind. You say Mannkind has proven success? I've been following Mannkind for 8 years. You have a strange definition for success, unless your talking about losing $, tooting their own horns, and steeling from peter to pay paul. I said MannKind has proven success in developing DPI medicines. See: Afrezza, Treprostinil Technosphere, and the Pipeline. MannKind currently has a 100% success rate with FDA product approval. Their first biological product (Afrezza) that they developed for FDA approval was approved. That equates to a 100% FDA product approval success rate. Yes, you are factually correct. I was referring to shareholder value, funny how the word success is used and interpreted. |
|
|
|
Post by goyocafe on Apr 30, 2020 11:43:31 GMT -5
Interview with Gilead CEO today. www.msn.com/en-us/finance/markets/gilead-ceo-says-over-50000-remdesivir-courses-ready-to-ship/ar-BB13oJre The following statement is interesting: " The current version of the drug is infused, which would make it less convenient to use in milder patients who are not hospitalized. O’Day said Gilead scientists are devising an inhaled formulation of the drug that would allow patients to breathe the medicine directly into their lungs. “We are moving with speed on it,” he said. He said he couldn’t give a timeline of when patient trials of the inhaled form would begin. " Yes, this is our ticket. GILD could buy MNKD in a blink of an eye? Effective drug delivery system. If this global catastrophe passes MNKD by without its ability to capitalize on it, and do good for society, I believe it will tell us all what the future of this company holds. |
|
|
|
Post by brotherm1 on Apr 30, 2020 12:35:51 GMT -5
Just playing the devil here, but would there be a reason for Gilead to use technosphere instead of aerosol or pump type inhaler like is often used for asthma ?
|
|
|
|
Post by mango on Apr 30, 2020 12:48:38 GMT -5
Just playing the devil here, but would there be a reason for Gilead to use technosphere instead of aerosol or pump type inhaler like is often used for asthma ? MannKind's DPI platform is superior to the outdated DPIs on the market and also outperform aerosol therapy as well. In addition, MannKind's inhalers are cheap to make. Furthermore, less treatment burden, drawbacks and limitations are associated with MannKind's DPI platform compared with aerosol therapy and DPIs and MDIs on the market today. I have covered the comparisons in past posts if you search for it you will find them where I went into great detail (I don't have time at the moment to search for them). 🤘 |
|
|
|
Post by boca1girl on Apr 30, 2020 13:04:56 GMT -5
A good analyst should make this their first question on the earnings call. Have their been any conversations with Gilead with regards to their stated goal of an inhaled version of Remdesivir? That would be a BAD question because he does not know the answer. If Mike answered NO....it could hurt the stock price. And Mike wont say yes because they are still working out the details of a possible collaboration. I think it would be a great question. MNKD just has to reply with “We can’t comment on that”. |
|
|
|
Post by brotherm1 on Apr 30, 2020 13:20:43 GMT -5
Just playing the devil here, but would there be a reason for Gilead to use technosphere instead of aerosol or pump type inhaler like is often used for asthma ? MannKind's DPI platform is superior to the outdated DPIs on the market and also outperform aerosol therapy as well. In addition, MannKind's inhalers are cheap to make. Furthermore, less treatment burden, drawbacks and limitations are associated with MannKind's DPI platform compared with aerosol therapy and DPIs and MDIs on the market today. I have covered the comparisons in past posts if you search for it you will find them where I went into great detail (I don't have time at the moment to search for them). 🤘 . Is not their Remdesivir meant for those on ventilators only? If so, would they even be capable of inhaling well? |
|
|
|
Post by peppy on Apr 30, 2020 13:27:23 GMT -5
Just playing the devil here, but would there be a reason for Gilead to use technosphere instead of aerosol or pump type inhaler like is often used for asthma ? I believe so. Cayston® aztreonam for inhalation solution 75 mg/vial AmBisome® amphotericin b liposome for injection 50 mg/vial and their MAB's. www.gilead.com/science-and-medicine/pipeline |
|
